|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_ocn940961473 |
| 003 |
OCoLC |
| 005 |
20231120112054.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
160225s2016 enk o 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d UIU
|d YDXCP
|d OPELS
|d N$T
|d EBLCP
|d TEFOD
|d U3W
|d MERUC
|d D6H
|d OCLCQ
|d UKMGB
|d OCLCQ
|d S2H
|d OCLCO
|d OCLCQ
|
| 015 |
|
|
|a GBB624761
|2 bnb
|
| 016 |
7 |
|
|a 017745388
|2 Uk
|
| 019 |
|
|
|a 945611998
|
| 020 |
|
|
|a 9780323354080
|q (electronic bk.)
|
| 020 |
|
|
|a 0323354084
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323353236
|
| 035 |
|
|
|a (OCoLC)940961473
|z (OCoLC)945611998
|
| 050 |
|
4 |
|a RS201.N35
|
| 072 |
|
7 |
|a HEA
|x 012000
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 020000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 004000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 101000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 109000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 029000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 040000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 092000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 610.28
|2 23
|
| 245 |
0 |
0 |
|a Assessing nanoparticle risks to human health /
|c edited by Gurumurthy Ramachandran.
|
| 250 |
|
|
|a Second edition.
|
| 264 |
|
1 |
|a Oxford, UK :
|b William Andrew is an imprint of Elsevier,
|c 2016.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Micro and Nano Technologies
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed March 3, 2016).
|
| 505 |
0 |
|
|a Front Cover; Assessing Nanoparticle Risks to Human Health; Copyright Page; Contents; About the Editor; About the Contributors; Preface; 1 The Challenge of Nanomaterial Risk Assessment; 1.1 Introduction; 1.2 The Nature of the Nanomaterial Challenge; 1.3 The Problem with Definitions; 1.4 Principles-Based Problem Formulation for Engineered Nanomaterials; 1.4.1 Emergent Risk; 1.4.2 Plausibility; 1.4.3 Impact; 1.5 Applying the Three Principles to Engineered Nanomaterials; 1.5.1 Materials Demonstrating Abrupt Scale-Specific Changes in Biological or Environmental Behavior.
|
| 505 |
8 |
|
|a 1.5.2 Materials Capable of Penetrating Normally Inaccessible Places1.5.3 Active Materials; 1.5.4 Materials Exhibiting Scalable Hazard That Is Not Captured by Conventional Risk Assessments; 1.6 Responsible Research and Innovation; 1.7 Looking Forward; References; 2 Assessing and Managing Exposures to Nanomaterials in the Workplace; 2.1 A General Strategy to Assess Workplace Exposures; 2.2 Uncertainties Introduced by Nanotechnology; 2.3 Exposure Routes; 2.3.1 Inhalation; 2.3.2 Dermal Exposure; 2.3.3 Ingestion; 2.4 Occupational Exposure Limits; 2.4.1 Permissible Exposure Limits from the OSHA.
|
| 505 |
8 |
|
|a 2.4.2 Recommended Exposure Limits from the NIOSH2.4.3 Benchmark Limits; 2.5 Instruments Available to Assess Exposures; 2.5.1 Direct-Reading Instruments; Number concentration; Mass concentration; Surface area concentration; 2.5.2 Time-Integrated Measurements; Detailed characterization; Routine monitoring; 2.6 Specific "Best Practices" for Exposure Assessment Strategy in Nanotechnology; 2.6.1 Basic Characterization; Workplace and workforce; Characterizing nanomaterials; 2.6.2 Construction of Similar Exposure Groups Combined with Exposure Assessment; Concentration mapping.
|
| 505 |
8 |
|
|a Job-task-related measurementsBackground particles and incidental nanoparticles; 2.6.3 Interpretation of Exposure Assessment Results; Selecting occupational exposure limits; Defining the exposure profile; 2.6.4 Follow-Up and Control; References; 3 Hazard and Risk Assessment of Workplace Exposure to Engineered Nanoparticles: Methods, Issues, and Carbon Nanotub ... ; 3.1 Introduction; 3.1.1 Risk Assessment Paradigm; 3.1.2 Hazard Assessment; 3.1.3 Dose-Response Assessment; No observed or lowest observed adverse effect levels; Benchmark dose methods; Comparison of BMD and NOAEL/LOAEL estimates.
|
| 505 |
8 |
|
|a 3.1.4 Interspecies and Temporal Extrapolation3.2 Case Study Example: Carbon Nanotubes; 3.2.1 Data Description; 3.2.2 Severity of Effects; 3.2.3 Quantitative Risk Assessment Procedures; Step 1. Evaluation of the exposure (or dose) and response data; Step 2. Estimation of a point of departure; Step 3. Estimation of rat lung dose; Step 4. Estimation of human-equivalent lung dose; Step 5. Risk characterization; 3.2.4 Considerations in the Derivation of OELs; 3.3 Discussion; 3.3.1 Comparison with Other Methods; 3.3.2 Research Needs; 3.3.3 Future Directions; References.
|
| 650 |
|
0 |
|a Nanoparticles
|x Risk assessment.
|
| 650 |
|
6 |
|a Nanoparticules
|0 (CaQQLa)201-0262530
|x �Evaluation du risque.
|0 (CaQQLa)201-0385652
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Holism.
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Reference.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Alternative Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Atlases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Essays.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Family & General Practice.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Holistic Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Osteopathy.
|2 bisacsh
|
| 700 |
1 |
|
|a Ramachann, Gurumurthy,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Ramachandran, Gurumurthy.
|t Assessing Nanoparticle Risks to Human Health.
|d : Elsevier Science, �2016
|z 9780323353236
|
| 830 |
|
0 |
|a Micro & nano technologies.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323353236
|z Texto completo
|
